Alpha Tau Medical (DRTS) said Monday it released interim data from a US clinical trial evaluating its radiation treatment in three patients with a recurrent form of brain cancer.
Two participants achieved a complete response with the disappearance of tumor lesions, while the third showed a 30% reduction in tumor size, the company said.
The safety review noted one serious adverse event involving a seizure and temporary paralysis that was subsequently resolved with steroids, it said.
Shares of the company were up over 20% in Monday premarket activity.
Price: 10.25, Change: +1.74, Percent Change: +20.48
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments